Your browser doesn't support javascript.
loading
[Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation]. / Olaparib ­ cancer de prostate métastatique résistant à la castration muté BRCA.
Saillant, Arnaud; Flippot, Ronan.
Affiliation
  • Saillant A; Centre hospitalo-universitaire de Poitiers, département d'oncologie médicale, 86021 Poitiers, France. Electronic address: arnaud.saillant@gmail.com.
  • Flippot R; Gustave-Roussy, département de médecine oncologie, Villejuif, France.
Bull Cancer ; 108(2): 140-142, 2021 Feb.
Article in Fr | MEDLINE | ID: mdl-33546874
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phthalazines / Piperazines / Genes, BRCA1 / Genes, BRCA2 / Prostatic Neoplasms, Castration-Resistant / Mutation / Antineoplastic Agents Limits: Humans / Male Country/Region as subject: Europa Language: Fr Journal: Bull Cancer Year: 2021 Document type: Article Country of publication: Francia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phthalazines / Piperazines / Genes, BRCA1 / Genes, BRCA2 / Prostatic Neoplasms, Castration-Resistant / Mutation / Antineoplastic Agents Limits: Humans / Male Country/Region as subject: Europa Language: Fr Journal: Bull Cancer Year: 2021 Document type: Article Country of publication: Francia